Recode Health Ventures

Recode Health Ventures has not publicly identified the general partners or managing directors who lead investment decisions. Public records and official communications do not list any named principals for the firm. Institutional allocators should request a direct disclosure before proceeding with due diligence.

The firm has not publicly described its sourcing model. Given its narrow healthcare-sector focus, it likely relies on practitioner networks, industry conferences, and referrals from healthcare operators. However, no specific sourcing strategy has been disclosed in any known publication.

The firm is classified as a venture capital firm in public filings. It has not disclosed whether it operates with single-family-office backing or institutional LP capital. The lack of public AUM data leaves this structural question unresolved.

Recode Health Ventures appears to be a direct venture investor, not a fund-of-funds or secondary investor. There is no public record of the firm making commitments to external venture funds. It makes direct equity investments in early-stage healthcare technology companies.

Based on SEC filings and public signals, the firm targets Seed through Series A rounds. It has not disclosed an average check size or pre-money valuation range. The firm does not appear to be active in growth-stage (Series C and later) or crossover investments.

The firm is exclusively healthcare-focused and explicitly avoids non-healthcare sectors such as enterprise software, fintech, and consumer technology. Within healthcare, it avoids traditional life sciences (biotech, pharma) and medical device companies. It focuses on software-enabled services and platforms for providers, payers, and patients.

The source of the firm's capital has not been publicly disclosed. It is not known whether Recode Health Ventures is backed by a specific family fortune, institutional endowments, or high-net-worth individuals. The firm does not publish its investor base.